The team consists of individuals with deep experience in rare diseases, including co-founding the successful orphan drug development companies BioMarin, Raptor Pharma, and Wilson Therapeutics. Recent leadership expansion includes appointment of Chief Commercial and Strategy Officer to build commercial infrastructure ahead of the planned FDA NDA submission.
Cyborg Score Rationale
Analyst consensus is Buy with 11 analysts covering the stock and a 2026 price target of $107. The imminent FDA filing for ALXN1840 represents a significant near-term catalyst. However, weaknesses in intellectual property protection create uncertainties surrounding long-term viability of the drug pipeline.
Top Insights
Planned H1 2026 FDA NDA submission for ALXN1840 (Wilson disease) represents major regulatory milestone and near-term catalyst
ALXN1840 demonstrates clinical efficacy with rapid copper balance improvement and sustained neurological benefit in Phase 2 trials
MNPR-101 radiopharmaceutical platform targets uPAR-expressing tumors across multiple cancer types including pancreatic, breast, and colorectal cancers
100% of covering analysts recommend Buy or Strong Buy, indicating strong conviction in pipeline potential
Named Competitors
Wilson Disease Therapies — Rare disease treatment development
Radiopharmaceutical Platforms — Medical imaging and diagnostics
Rare Oncology Therapeutics — Specialty oncology development
Recent Developments
(March 2026) Appointed Susan Rodriguez as Chief Commercial and Strategy Officer to lead commercial infrastructure build-out ahead of ALXN1840 NDA submission
(January 2026) Morgan Stanley initiated coverage with Overweight recommendation
(November 2025) Chardan Capital maintained Buy rating; Raymond James downgraded from Strong Buy to Outperform
Open the full interactive Monopar Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.